Volume 40, Issue 5, Pages (May 2014)

Slides:



Advertisements
Similar presentations
Mechanisms of HIV-1 Resistance to ADCC David Evans University of Wisconsin-Madison July 26, 2017 “No conflicts of interest to declare”
Advertisements

Volume 17, Issue 5, Pages (May 2015)
Volume 20, Issue 8, Pages (August 2017)
Volume 46, Issue 5, Pages e3 (May 2017)
Volume 156, Issue 4, Pages (February 2014)
Peter D. Kwong, John R. Mascola  Immunity 
M. Juliana McElrath, Barton F. Haynes  Immunity 
Volume 43, Issue 5, Pages (November 2015)
Volume 158, Issue 6, Pages (September 2014)
Volume 14, Issue 5, Pages (November 2013)
Volume 165, Issue 7, Pages (June 2016)
Volume 159, Issue 1, Pages (September 2014)
Volume 17, Issue 3, Pages (March 2015)
Volume 37, Issue 5, Pages (March 2010)
Volume 11, Issue 10, Pages (June 2015)
HIV Immunology Goes Out On a Limb
Volume 42, Issue 2, Pages (February 2015)
Volume 46, Issue 6, Pages e6 (June 2017)
Volume 23, Issue 11, Pages (June 2018)
Volume 47, Issue 3, Pages e3 (September 2017)
Model Building and Refinement of a Natively Glycosylated HIV-1 Env Protein by High- Resolution Cryoelectron Microscopy  Jeong Hyun Lee, Natalia de Val,
Volume 159, Issue 1, Pages (September 2014)
The Rational Design of an AIDS Vaccine
Volume 18, Issue 12, Pages (December 2010)
Volume 44, Issue 5, Pages (May 2016)
Alice C.L. Len, Shimona Starling, Maitreyi Shivkumar, Clare Jolly 
Volume 14, Issue 11, Pages (March 2016)
Volume 16, Issue 9, Pages (August 2016)
B-1a and B-1b Cells Exhibit Distinct Developmental Requirements and Have Unique Functional Roles in Innate and Adaptive Immunity to S. pneumoniae  Karen.
Volume 50, Issue 1, Pages e6 (January 2019)
Volume 43, Issue 6, Pages (December 2015)
Volume 40, Issue 5, Pages (May 2014)
HIV-1 neutralizing antibodies induced by native-like envelope trimers
Volume 46, Issue 4, Pages (April 2017)
Volume 17, Issue 4, Pages (April 2010)
Volume 23, Issue 2, Pages (April 2018)
Volume 23, Issue 10, Pages (October 2015)
Volume 1, Issue 2, Pages (April 2007)
Alexander Falkenhagen, Sadhna Joshi  Molecular Therapy - Nucleic Acids 
Adam S. Dingens, Hugh K. Haddox, Julie Overbaugh, Jesse D. Bloom 
Volume 23, Issue 1, Pages (April 2018)
Volume 14, Issue 5, Pages (November 2013)
Volume 28, Issue 6, Pages (June 2008)
Volume 21, Issue 10, Pages (December 2017)
Volume 22, Issue 2, Pages (February 2005)
Glycoprotein Structural Genomics: Solving the Glycosylation Problem
Volume 35, Issue 2, Pages (August 2011)
Volume 23, Issue 3, Pages (April 2018)
Volume 25, Issue 5, Pages e5 (May 2017)
Mechanism of Human Antibody-Mediated Neutralization of Marburg Virus
May K. Wang, Sun-Young Lim, Soo Mi Lee, James M. Cunningham 
Volume 19, Issue 2, Pages (February 2012)
Volume 8, Issue 4, Pages (October 2010)
Infectious Entry and Neutralization of Pathogenic JC Polyomaviruses
Volume 19, Issue 2, Pages (April 2017)
Volume 9, Issue 1, Pages (January 2011)
A Stable Prefusion Intermediate of the Alphavirus Fusion Protein Reveals Critical Features of Class II Membrane Fusion  Claudia Sánchez-San Martín, Hernando.
Bispecific Antibodies Against HIV
Volume 7, Issue 3, Pages (May 2014)
Volume 17, Issue 5, Pages (May 2015)
Volume 17, Issue 3, Pages (March 2015)
Volume 38, Issue 2, Pages (February 2013)
Volume 49, Issue 2, Pages e8 (August 2018)
A Blueprint for HIV Vaccine Discovery
HIV Broadly Neutralizing Antibodies: Taking Good Care Of The 98%
Volume 25, Issue 6, Pages e5 (June 2019)
Volume 114, Issue 2, Pages (July 2003)
Hitting HIV’s Harpoon Immunity
Volume 13, Issue 1, Pages (January 2013)
Volume 19, Issue 2, Pages (April 2017)
Presentation transcript:

Volume 40, Issue 5, Pages 657-668 (May 2014) Broadly Neutralizing HIV Antibodies Define a Glycan-Dependent Epitope on the Prefusion Conformation of gp41 on Cleaved Envelope Trimers  Emilia Falkowska, Khoa M. Le, Alejandra Ramos, Katie J. Doores, Jeong Hyun Lee, Claudia Blattner, Alejandro Ramirez, Ronald Derking, Marit J. van Gils, Chi-Hui Liang, Ryan Mcbride, Benjamin von Bredow, Sachin S. Shivatare, Chung-Yi Wu, Po-Ying Chan-Hui, Yan Liu, Ten Feizi, Michael B. Zwick, Wayne C. Koff, Michael S. Seaman, Kristine Swiderek, John P. Moore, David Evans, James C. Paulson, Chi-Huey Wong, Andrew B. Ward, Ian A. Wilson, Rogier W. Sanders, Pascal Poignard, Dennis R. Burton  Immunity  Volume 40, Issue 5, Pages 657-668 (May 2014) DOI: 10.1016/j.immuni.2014.04.009 Copyright © 2014 Elsevier Inc. Terms and Conditions

Figure 1 PGT151-158 Neutralization of an Indicator Panel of Five Pseudoviruses Serial dilutions of antibody were preincubated with pseudovirus for 1 hr and then added to TZM-bl cells. Three days after infection luciferase values were measured, and percent neutralization was calculated. Data are from one representative experiment of at least two replicate experiments and are presented as the mean of two replicate wells ± SEM. Immunity 2014 40, 657-668DOI: (10.1016/j.immuni.2014.04.009) Copyright © 2014 Elsevier Inc. Terms and Conditions

Figure 2 PGT151 and PGT152 Binding to Different Forms of Env (A) PGT151 and PGT152 do not bind to JR-FL gp120 monomer as measured by ELISA. Data for (A) and (C) are presented as the mean of two replicates ± SEM. (B) PGT151 binds to native, cleaved (cl) but not to uncleaved (uncl) JR-FL E168K trimers expressed on the surface of 293T cells, as measured by flow cytometry. Data are from a representative experiment of two replicate experiments. (C) PGT151 and PGT152 bind to cleaved soluble BG505 SOSIP.664 gp140 trimers but not to the corresponding uncleaved gp140 trimers, as measured by ELISA. See also Figure S2. Immunity 2014 40, 657-668DOI: (10.1016/j.immuni.2014.04.009) Copyright © 2014 Elsevier Inc. Terms and Conditions

Figure 3 PGT151–PGT158 Bind Complex-Type Glycans (A) PGT151 and PGT152 neutralization of JR-CSF pseudovirus generated (1) in the presence of the glycosidase inhibitor swainsonine, which prevents the formation of complex glycans by inhibiting the trimming of mannose residues from the Man-α6 arm of the GlcNAcMan5GlcNAc2 structure, or (2) in 293S cells (GNT1−/− cells), a cell line that is deficient in N-acetylglucosaminyltransferase I and is unable to add a GlcNAc residue to the Man5GlcNAc2 structure to permit processing to complex glycans. Neutralization of JR-SCF pseudovirus by 2G12 is not affected by either (1) or (2) because it binds exclusively to high-mannose glycans on the glycan shield of Env. Data are presented as the mean ± SEM. (B) PGT151–PGT158 bind tetra-antennary complex carbohydrates and that PGT151 additionally binds a triantennary glycan, on the Wong glycan array. Data are presented as the mean ± SD. (C) Most of the PGT151 family MAbs do bind triantennary complex-type glycans on the CFG microarray. (D) PGT151 and PGT152 bind a tetrantennary complex-type glycan on the neoglycolipid microarray. The symbols for common monosaccharides are as follows: purple diamonds represent sialic acid, yellow circles represent galactose, red triangles represent fucose, blue squares represent N-acetyl glucosamine, and green circles represent mannose. See also Tables S4 and S5. Data for the CFG microarray are presented as the mean ± SEM. Small differences in array results might reflect differences in glycan coating densities. Immunity 2014 40, 657-668DOI: (10.1016/j.immuni.2014.04.009) Copyright © 2014 Elsevier Inc. Terms and Conditions

Figure 4 PGT151 Neutralization of Viruses Containing N611A, N637A, and E647A Single and Double Alanine Substitutions Serial dilutions of antibody (A) PGT151 and (B) PGV04, used as a control, were preincubated with pseudovirus for 1 hr and then added to TZM-bl cells. Three days after infection, luciferase values were measured and percent neutralization was calculated. See also Figure S4. Data are from a representative experiment of at least two replicate experiments and are presented as the mean values of two replicate wells ± SEM. Immunity 2014 40, 657-668DOI: (10.1016/j.immuni.2014.04.009) Copyright © 2014 Elsevier Inc. Terms and Conditions

Figure 5 ADCC by PGT151 and PGT152 (A) PGT151 and (B) PGT152 were titered for ADCC activity against target cells infected with HIV-1 NL4-3, YU2, JR-CSF, and SIVmac239, and an NK cell line (KHYG-1) expressing CD16 was used as the effector cell. The killing of virus-infected cells by ADCC is indicated by a loss of relative light units (RLUs). SIVmac239 is used as a negative control, and HIVIG is used as a positive control. Data are presented as mean values of three replicates ± SEM. Immunity 2014 40, 657-668DOI: (10.1016/j.immuni.2014.04.009) Copyright © 2014 Elsevier Inc. Terms and Conditions